Trial Profile
A phase II study of clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (Decadron) for newly diagnosed subjects with multiple myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 May 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Clarithromycin; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms BiRD
- 19 May 2021 Status changed from active, no longer recruiting to completed.
- 13 Feb 2017 Planned End Date changed from 1 May 2010 to 1 Aug 2022.
- 29 Dec 2009 Planned end date (1 May 2010) added as reported by ClinicalTrials.gov.